No Data Yet
The 67th ASH Annual Meeting presented revolutionary clinical data for multiple myeloma, with therapies like CARVYKTI demonstrating the potential for functional cures. These findings are set to alter treatment paradigms and attract significant investment into the oncology sector.
Recent clinical trial advancements in targeted and gene-editing therapies signal a significant shift in the oncology market. An innovative 'off-the-shelf' T-cell therapy has shown promise in early trials for leukemia, while major pharmaceutical firms are advancing pivotal studies for novel cancer drugs.
HanchorBio has announced its cancer immunotherapy candidate, HCB101, has been selected for an oral presentation at the ESMO Immuno-Oncology Congress 2025. This provides a crucial platform to unveil clinical data that will be closely watched by investors and the pharmaceutical industry.
AbbVie's oncology division reported a 3% year-over-year revenue increase in the first nine months of 2025, reaching over 11% of the company's total revenue. This growth is driven by a successful strategic shift, with sales from newer drugs offsetting the decline of its former blockbuster, Imbruvica, indicating a robust pipeline transition.
IDEAYA Biosciences has fully enrolled its pivotal Phase 2/3 clinical trial for a new metastatic uveal melanoma therapy. This operational milestone is critical for advancing the drug combination toward potential FDA submission and commercialization, targeting a high unmet medical need.